News
HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...
The Foreign Secretary gave a speech at The Africa Debate on 2 July 2025. Ladies and Gentleman, Friends.It's a great, great ...
A team of leading infectious disease scientists from academia and industry have been awarded £17.9 million to identify new ...
A team of leading infectious disease scientists from academia and industry have been awarded £17.9 million to identify new ...
BactiVac showcases expertise at the World Vaccine Congress 2025, championing global equity and innovation in bacterial vaccine development.
Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...
The sharpest fall was seen at the brand level, with only 14 brands advertising during the 2025 final, a drastic drop from 70 ...
2d
Zacks Investment Research on MSNMerck Starts Phase III Studies on Once-Monthly Pill for HIV PreventionMerck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...
A team of infectious disease scientists have been awarded £17.9m to identify new drugs to treat fungal infections.
South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research ...
Talks with the South African government have so far yielded little progress to avert the closure of loss-making long steel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results